Scarica l'app Stockscreener
25.39
46.61%
-22.16
Precedente Chiudi:
$47.55
Aprire:
$25.69
Volume 24 ore:
105
Relative Volume:
66.00
Capitalizzazione di mercato:
$2.27B
Reddito:
-
Utile/perdita netta:
$-104.24M
Rapporto P/E:
-10.85
EPS:
-2.34
Flusso di cassa netto:
$-87.22M
1 W Prestazione:
-46.61%
1M Prestazione:
-46.61%
6M Prestazione:
-46.61%
1 anno Prestazione:
-46.61%
Intervallo 1D:
$25.69
$25.69
Intervallo di 1 settimana:
$25.69
$25.69
Portata 52W:
$25.69
$25.69
Dice Therapeutics Inc Stock (DICE) Company Profile
Nome
Dice Therapeutics Inc
Settore
Industria
Telefono
650-566-1402
Indirizzo
279 East Grand Avenue, Suite 300 Lobby B, South San Francisco
Compare DICE vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DICE
Dice Therapeutics Inc
|
25.69 | 2.27B | 0 | -104.24M | -87.22M | -2.34 |
VRTX
Vertex Pharmaceuticals Inc
|
522.09 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.91 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.40 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.63 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.24 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dice Therapeutics Inc Stock (DICE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-03-31 | Iniziato | Needham | Buy |
| 2023-03-01 | Iniziato | Cowen | Outperform |
| 2023-03-01 | Iniziato | TD Cowen | Outperform |
| 2022-11-15 | Iniziato | Guggenheim | Buy |
| 2022-09-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-09-07 | Iniziato | Stifel | Buy |
| 2022-07-18 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-11 | Iniziato | BofA Securities | Buy |
| 2021-10-11 | Iniziato | Evercore ISI | Outperform |
| 2021-10-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Dice Therapeutics Inc Borsa (DICE) Ultime notizie
DICE Therapeutics Inc. (DICE) Peer Comparison – Compare with Others - Value Research
Ambros Therapeutics Announces Appointments of John C. Jacobs and Scott Robertson to Board of Directors - The Manila Times
Autoimmune Treatment Market Report Examines Industry Trends, Growth Drivers And Future Outlook - openPR.com
DHI Group (DHX) Stock Sees Fair Value Lift As Analysts Weigh ClearanceJobs And Dice - Yahoo Finance
Segment Overview and Major Growth Areas in the Urokinase Market - openPR.com
CAPR Stock Drop: Capricor Therapeutics Clinical Data Leads to 64% Stock Drop and Securities Fraud Class Action for Investors - PR Newswire
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology - Eli Lilly and Company
A 'Made in the USA' Monopoly edition cost twice as much to build — and no US factory could even make the dice - Yahoo Finance
An InventHelp 123Invent Client Develops New Money Themed Dice Game (LBT-9813) - Yahoo Finance
The EU rolls dice by setting unambiguous parameters for Satcos operating in 2GHz - Yahoo Finance
Tech Professionals Find Relevant Roles Faster with Dice’s LLM Connector - Yahoo Finance
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% - The Motley Fool
Morningstar Sees SpaceX Worth Half Its IPO Price - thedeepdive.ca
OpenAI Files Confidential S-1 With SEC, Targeting IPO as Soon as Q4 - thedeepdive.ca
SpaceX Cuts IPO Valuation Target to $1.8 Trillion After Investor Feedback - TheDeepDive.ca
TWO DICE SECURES STRATEGIC INVESTMENT FROM OAK VIEW GROUP - Yahoo Finance
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire
Russia is about to roll the dice on crypto regulation. Here’s its playbook - Yahoo Finance
Jim Cramer on JetBlue Airways: “It’s a Dice Roll, and I Don’t Like Dice Rolls” - Yahoo Finance
EA Slashes Battlefield Headcount In a Pivot to AI - Yahoo Finance
Burnout, layoffs, 'ghost jobs' in Dice's 2026 tech survey - Stock Titan
Muted and missing M&As: JPM deals absent in 2026 - bioworld.com
Baron of Dice Answers the Questions Players Keep Asking - Yahoo Finance
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs - BioPharma Dive
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
Boyd Gaming reveals $160M revamp for Par-A-Dice Casino - Yahoo Finance
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes - American Heart Association Journals
Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
Don't Buy Summit Therapeutics Until This Big Thing Happen - The Motley Fool
Big pharma drives surge in biopharma job cuts in 2025 - BioWorld News
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy - Business Wire
RNA Therapeutics Market Size to Reach USD 26.13 Billion by 2034 - BioSpace
Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight - PR Newswire
Formulation specialist Azurity to lay off 75 amid plans to sunset Massachusetts plant - Fierce Pharma
Fever Acquires Ticketing Platform Dice - Yahoo Finance
Forward Therapeutics, the first biotech from Curie.Bio, raises $50M for oral small molecules in immunology - Endpoints News
DHI Group Inc (DHX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Focus - Yahoo Finance
15 Best Growth Stocks to Buy for the Next 3 Years - Insider Monkey
Dice Therapeutics Stock Price, News & Analysis - Stock Titan
Biopharma restructurings reflect strategy of short-term pain for long-term gains - BioWorld News
10 Best Low Volatility Stocks to Buy Now - Insider Monkey
The top 10 pharma R&D budgets for 2024 - Fierce Biotech
Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) - GlobeNewswire
Sage lawsuit enforces standstill as board evaluates Biogen offer - BioWorld News
The top 10 biopharma M&A deals of 2024 - Fierce Pharma
Gambling.com Rolls The Dice On OddsJam's Parent; $80M Upfront Consideration For Instant Revenue Boost - Yahoo Finance
Combos, New MOAs, And Oral Formulations Of Injectables: Lilly’s Immunology Strategy - insights.citeline.com
Why Did Eli Lilly Stock Fall 6%? - Trefis
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products - Eli Lilly and Company
Mounjaro To Lead Eli Lilly’s Q3 Growth - Trefis
Dice Therapeutics Inc Azioni (DICE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.30%
0.62%
Capitalizzazione:
|
Volume (24 ore):